2,4,6-Trinitrotoluene (TNT)

CASRN 118-96-7

  • IRIS Summary (PDF) (14 pp, 118 K)
  • Status: 2,4,6-Trinitrotoluene (TNT) is not being reassessed by IRIS at this time.

Health Hazard Assessments for Effects Other than Cancer


Reference Dose for Oral Exposure (RfD) (PDF) (14 pp, 118 K) last updated: 09/26/1988

RfD (mg/kg-day) System Basis PoD Composite UF Confidence
5 x10-4 Hepatic Liver effects LOAEL : 5 x10-1
mg/kg-day
1000 Medium

Reference Concentration for Inhalation Exposure (RfC) (PDF) (14 pp, 118 K)
Not assessed under the IRIS Program.

Cancer Assessment


Weight of Evidence for Cancer (PDF) (14 pp, 118 K) last updated: 06/01/1989

WOE Characterization Framework for WOE Characterization
C (Possible human carcinogen) Guidelines for Carcinogen Risk Assessment (US EPA, 1986)
Basis:
  • Evidence of human carcinogenicity is inadequate. Urinary bladder papilloma and carcinoma were observed in female Fischer 344 rats. Mutagenic activity was observed in Salmonella with and without metabolic activation.
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (14 pp, 118 K)

Oral Slope Factor: 3.0 x10 -2 per mg/kg-day
Drinking Water Unit Risk: 9.0 x10 -7 per µg/L
Extrapolation Method: Linearized multistage procedure, extra risk
Tumor site(s): Urinary
Tumor type(s): Urinary bladder, transitional cell papilloma and transitional squamous cell carcinomas (U.S. DOD, 1984a)


Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (14 pp, 118 K)

Not Assessed under the IRIS Program.

You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.